Novel dynamic outcome indicators and clinical endpoints in myelodysplastic syndromes; the EUMDS Registry and MDS-RIGHT project perspective

Theo De Witte, Luca Malcovati, Pierre Fenaux, David Bowen, Argiris Symeonidis, Moshe Mittelman, Reinhard Stauder, Guillermo Sanz, Jaroslav ermák, Saskia Langemeijer, Eva Hellström-Lindberg, Ulrich Germing, Mette Skov Holm, Krzysztof Mdry, Aurelia Tatic, António Medina Almeida, Aleksandar Savic, Inga Mandac Rogulj, Raphael Itzykson, Marlijn Hoeks, Hege Gravdahl Garelius, Dominic Culligan, Ioannis Kotsianidis, Lionel Ades, Arjan A. van de Loosdrecht, Corine van Marrewijk, Ge Yu, Simon Crouch, and Alexandra Smith

Disclosures: TdW: research funding from Amgen, Celgene, and Novartis, as project coordinator EUMDS; PF: research funding and honoraria from Amgen, Astex, Celgene, Janssen, Novartis, and Roche, and consulting fees from Amgen, Boehringer-Ingelheim, Celgene and Janssen; ASy: honoraria and consulting fees from Amgen, Celgene/GenesisPharma, Genzyme/Sanofi, Gilead, Janssen-Cilag, Pfizer, MSD, and Novartis; MM: research funding from Amgen/Medison, Celgene/Néopharm, GSK, Johnson & Johnson, Novartis, and Roche, honoraria from Pfizer, Amgen, and consulting fees from Amgen, Celgene, and Janssen; RS: research funding and honoraria from Celgene, Teva and Novartis; GS: research funding and honoraria from Amgen, Celgene, and Novartis, and consulting fees from Amgen, Boehringer-Ingelheim, Celgene, MSD, and Novartis; EHL: research funding from Celgene; UG: research funding and honorarium from Novartis; MSH: research funding from Celgene; AMA: honoraria from Alexion and BMS, and consulting fees from Celgene, Novartis, and Servier; ASa: has received honoraria and consulting fees from Amgen, Hoffmann-La Roche, MSD, Novo Nordisk, Pfizer, and Seattle Genetics; RI: research funding from Janssen, Oncoethix (now Merck MSD), and Novartis, honoraria from Amgen, BMS, Celgene, Janssen, Novartis and Sanofi, and consulting fees from Karyopharm, Novartis, and Otsuka; HGG: honoraria from Celgene, Novartis and Alexion; AvdL: research funding from Alexion and Celgene and honoraria from Celgene, Novartis, Amgen; CvM: project manager of the EUMDS Registry, is funded by the EUMDS and MDS-RIGHT project budget; ASm: research funding from Novartis, Roche, Pfizer, Takeda, Cilag-Janssen and Boehringer Ingelheim; The remaining authors (LM, DB, JC, SL, KM, AT, IMR, MH, DC, IK, LA, GY, Scr) declare no competing financial interests.

Contributions: Design: TdW, LM, CvM, RI, RS, EHL, HGG, MH, ASm, and DB; provision of patients, assembly of data: PF, DB, ASy, MM, RS, GS, JC, SL, EHL, LM, UG, MSH, KM, AT, AMA, ASa, IMR, RI, HGG, DC, IK, LA, AvdL, GY, ASm, CvM; statistical analysis and interpretation: GY, Scr, ASm, RI, MH, TdW, DB, CvM, RS, SL; manuscript writing: all authors; & #64257; nal approval: all authors.